A 62-year-old man with chronic kidney disease (eGFR 28 mL/min/1.73m²) and a urinary tract infection caused by Pseudomonas aeruginosa is being considered for aminoglycoside therapy. Which feature most reliably distinguishes the nephrotoxicity risk profile of tobramycin from that of gentamicin in this clinical context?

See the options, answer & explanation

Sign in free to reveal the answer choices, the correct answer, the detailed explanation, and AI-powered insights for this question.